Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

Published:2023-03-22 Issue:2 Volume:199 Page:243-252
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Rastogi Priya,Tang Gong,Hassan Saima,Geyer Charles E.,Azar Catherine A.,Magrinat Gustav C.,Suga J. Marie,Bear Harry D.,Baez-Diaz Luis,Sarwar Shakir,Boileau Jean-Francois,Brufsky Adam M.,Shibata Henry R.,Bandos Hanna,Paik Soonmyung,Yothers Greg,Swain Sandra M.,Mamounas Eleftherios P.,Wolmark Norman

Funder

GlaxoSmithKline

NSABP Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-023-06881-8.pdf

Reference24 articles.

1. Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384. https://doi.org/10.1016/S0140-6736(09)61964-4

2. Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

3. Burris HA 3rd, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313. https://ascopubs.org/doi/full/10.1200/JCO.2005.16.584

4. Blackwell K, Kaplan E, Franco S et al (2004) A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol 15:27. https://doi.org/10.1093/oxfordjournals.annonc.a000353

5. Burstein H, Storniolo AM, Franco S et al (2004) A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 15:27. https://doi.org/10.1093/oxfordjournals.annonc.a000353

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

3. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

4. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis;Therapeutic Advances in Medical Oncology;2024-01

5. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3